Mitigating antimicrobial resistance by innovative solutions in AI (MARISA): a modified James Lind Alliance analysis

利用人工智能创新解决方案缓解抗菌素耐药性(MARISA):一项改进的詹姆斯·林德联盟分析

阅读:1

Abstract

Antimicrobial resistance (AMR) is a critical global health threat and artificial intelligence (AI) presents new opportunities for our response. However, research priorities at the AI-AMR intersection remain undefined. This study aimed to identify and prioritise key areas for future investigation. Using a modified James Lind Alliance approach, we conducted semi-structured interviews with eight experts in AI and AMR between February and June 2024. Analysis of 338 coded responses revealed 44 distinct themes. Major barriers included fragmented data access, integration challenges and economic disincentives. The top ten priorities identified were: Combination Therapy, Novel Therapeutics, Data Acquisition, AMR Public Health Policy, Prioritisation, Economic Resource Allocation, Diagnostics, Modelling Microbial Evolution, AMR Prediction and Surveillance. A notable limitation was the underrepresentation of data from high-burden regions, limiting the generalisability of findings. To address these gaps, we propose the novel BARDI framework: Brokered Data-sharing, AI-driven Modelling, Rapid Diagnostics, Drug Discovery and Integrated Economic Prevention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。